Reply to Chu Et Al., "Adoption of the New CLSI Fluoroquinolone Breakpoints for "
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Vasallo F, Martin-Rabadan P, Alcala L, Garcia-Lechuz J, Rodriguez-Creixems M, Bouza E
. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis. 1998; 26(2):535-6.
DOI: 10.1086/517087.
View
2.
Chu Y, Tse H, Tsang D
. Adoption of the New CLSI Fluoroquinolone Breakpoints for . J Clin Microbiol. 2019; 57(11).
PMC: 6813013.
DOI: 10.1128/JCM.01176-19.
View
3.
Crump J, Barrett T, Nelson J, Angulo F
. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi salmonellae. Clin Infect Dis. 2003; 37(1):75-81.
DOI: 10.1086/375602.
View
4.
Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P
. Detection of decreased fluoroquinolone susceptibility in Salmonellas and validation of nalidixic acid screening test. J Clin Microbiol. 1999; 37(11):3572-7.
PMC: 85694.
DOI: 10.1128/JCM.37.11.3572-3577.1999.
View
5.
Naber K, Schito G, Botto H, Palou J, Mazzei T
. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): implications for empiric therapy. Eur Urol. 2008; 54(5):1164-75.
DOI: 10.1016/j.eururo.2008.05.010.
View